February 27-28 2012 Star Ratings Symposium
Star Ratings Symposium February 27-28 2012 Crowne Plaza Anaheim Resort, Anaheim, CA How would your rank your strategy for optimizing CMS’s 5-Star Quality Rating […]
LoneStar Heart is Focused on Preserving & Restoring Heart Functions to Heart Failure Patients
Congestive heart failure affects as many as 5 million Americans and with an aging population, more than half a million patients are diagnosed with the condition each year.
CorInnova is Developing Technologies to Restore Heart Function for Heart Failure Patients
CorInnova is currently trialing a cardiac compression device known as CorAmend that can be implanted and explanted without ever contacting the patient’s blood
Castlewood Surgical – Improving Coronary Bypass Grafting with “No Metal” Surgical Assistance
The Cyclone System allows a surgeon to eliminate the aortic side-biting clamp traditionally used in coronary artery bypass grafting (CABG).
Editor’s Note December 27, 2012
With a new year upon us, we are reminded of the year that is now coming to a close. 2011 has brought some amazing advancements […]
A New Era In Medical Devices Provides Critical Information in Real Time
The internet has ushered in a new era in Medical Devices as they begin to provide connectivity and communications to the health system to monitor the patient and provide critical clinical information.
Thermalin Diabetes Follows the “Coulter Process” And Addresses Significant Needs in the Insulin Market
Thermalin’s therapeutic proteins will address medical needs related to diabetes and its complications.
Anavex Life Sciences Challenges the Basic Assumptions In Treating Alzheimer’s Disease
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
Jeff Margolis Examines How Western Companies Can Capitalize on the Opportunities in India
India is emerging as a significant player in the life science sector. The 2005 patent amendments have brought India into the modern world in terms of intellectual property.
Vigilant Biosciences Aims to Lower Oral Cancer Mortality with Simple Screening Test
Nearly 40 percent of oral cancer patients will die within five years of diagnosis.